NCT04514081

The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma.

Status unknown Phase 2 Last updated 18 August 2020

What this trial tests

Phase 2 trial testing Chidamide; Decitabine; Camrelizumab in Hodgkin Lymphoma in 200 participants. Status unknown.

Timeline

1 August 2020

Primary endpoint
1 August 2022

1 August 2025

Quick facts

Lead sponsor	Chinese PLA General Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	200
Start date	1 August 2020
Primary completion	1 August 2022
Estimated completion	1 August 2025
Sites	1 location across China

Drugs / interventions tested

• Chidamide; Decitabine; Camrelizumab — full drug profile →
• Decitabine+Camrelizumab — full drug profile →

Conditions studied

• Hodgkin Lymphoma — all drugs for Hodgkin Lymphoma →
• Anti-PD-1 Antibody Resistant — all drugs for Anti-PD-1 Antibody Resistant →

Sponsor

Chinese PLA General Hospital

Who can join

Adults 12 to 75, any sex, with Hodgkin Lymphoma or Anti-PD-1 Antibody Resistant. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This open-label, randomized, two-arm, phase 2 study has the primary objective of comparing the ORR obtained with Chidamide+Decitabine+Camrelizumab against that obtained with Decitabine+Camrelizumab in patients with Hodgkin Lymphoma who were confirmed resistant to Anti-PD-1 antibody therapy.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets.
   Yang J, Xu J, Wang W, Zhang B, et al · · 2023 · cited 251× · PMID 37217462 · DOI 10.1038/s41392-023-01480-x
2. Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies.
   Zhao A, Zhou H, Yang J, Li M, et al · · 2023 · cited 81× · PMID 36797244 · DOI 10.1038/s41392-023-01342-6
3. Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment.
   Sun Y, Hong JH, Ning Z, Pan D, et al · · 2022 · cited 58× · PMID 36120308 · DOI 10.3389/fphar.2022.932914
4. New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities.
   Dai M, Liu M, Yang H, Küçük C, et al · · 2022 · cited 30× · PMID 36384676 · DOI 10.1186/s40164-022-00356-0
5. Epi-immunotherapy for cancers: rationales of epi-drugs in combination with immunotherapy and advances in clinical trials.
   Xu Y, Li P, Liu Y, Xin D, et al · · 2022 · cited 29× · PMID 35642676 · DOI 10.1002/cac2.12313
6. The epigenetic hallmarks of immune cells in cancer.
   Ji Y, Xiao C, Fan T, Deng Z, et al · · 2025 · cited 28× · PMID 40038722 · DOI 10.1186/s12943-025-02255-4
7. Converting "cold" to "hot": epigenetics strategies to improve immune therapy effect by regulating tumor-associated immune suppressive cells.
   Tang Y, Cui G, Liu H, Han Y, et al · · 2024 · cited 28× · PMID 38715348 · DOI 10.1002/cac2.12546
8. Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies.
   Kyriakidis I, Vasileiou E, Rossig C, Roilides E, et al · · 2021 · cited 24× · PMID 33807678 · DOI 10.3390/jof7030186